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ABSTRACT 
Chronotherapeutics is a method of treatment in which in-vivo drug availability is timed to match rhythms of disease, in order to optimize therapeutic outcomes and minimize 
side effects. From past several decades pulsatile delivery system has gained a lot interest as dosage form. Pulsatile delivery system aims to release drugs in planned pattern 
which means at appropriate time or at appropriate site. Several controlled release preparations are available which maintains constant drug concentration in the blood and 
tissues but it is not desired all the time as it has some side effects such as resistance, tolerability and drug side effects. Diseases wherein pulsatile drug delivery systems are 
effective include asthma, peptic ulcer, cardiovascular diseases, arthritis, attention deficit syndrome in children, and hypercholesterolemia. For preparing pulsatile delivery 
system, various design strategies have been proposed, most of them are time controlling, stimuli induced, externally regulated and multiparticulate formulations. Pulsatile 
delivery system is very much useful in case of drugs having chronopharmacological behavior, for the drug having high first pass metabolism effect and for those drugs which 
have specific site of adsorption in the GIT. Various polymeric materials are used in order to achieve desired lag time in pulsatile release dosage forms. The present article 
covers findings about the diseases which follows circardian rhythm and can be treated effectively by pulsatile delivery system. Here we also covered various methods of novel 
pulsatile drug delivery systems that might be able to release the therapeutic agents after proper lag time and at specific site of git. 
Keywords: Pulsatile Delivery, Chronotherapeutics, Circardian Rhythm. 
Introduction:[1-5] 
For  the  treatment  of  various  diseases  oral  route  is  the  most 
preffered route and conventional dosage forms are widely used 
for  treatment.    The  oral  route  of  drug  delivery  is  typically 
considered the favored and the most having the highest degree of 
patient  compliance  because  of  user-friendly  means  of  drug 
administration. Conventional drug delivery systems have targeted 
on constant or sustained drug output with the objective to optimize 
drug efficacy and to reduce adverse effects.Such dosage forms 
release drugs with constant or variable drug release. Diseases are 
being treated through delivery of the drug to the patient in the form 
of  various  conventional  dosage  forms.  All  these  dosage  forms 
have  to  be  administered  repetitively  for  maintaining  the  drug 
concentration  within  therapeutically  effective  range.  Controlled 
release medication deliver drug at constant level not as and when 
necessary. If diseases symptoms occur during specific time of day 
or night conventional dosage forms are unable to fulfill necessities 
of  conditions.  Modified  release  dosage  form  preparations  are 
expected  to  provide  reduce  dosing  frequency  and  improved 
patient compliance. There are other several problems regarding 
modified  dosage  form  preparations  such  as  resistance,  drug 
tolerance,  activation  of  physiological  systems  due  to  long  term 
constant drug concentration in the body. This challenge has been 
met by pulsatile dosage forms. Pulsatile release dosage forms are 
useful when constant plasma drug levels are not desired and that 
an  optimum  therapeutic  effects  comes  from  a  periodically 
fluctuating  drug concentration. Pulsatile systems are gaining a lot 
of interest as they deliver the drug at the right site of action at the 
right  time  and  in  the  right  amount,  thus  providing  spatial  and 
temporal  delivery  and  increasing  patient  compliance.  Pulsatile 
delivery system developed in order to fulfilling condition of rapid 
drug release after lag time.Circardian rhythm is the main factor 
affecting  on  development  of  pulsatile  drug  release.  Pulsatile 
delivery system is very much useful when constant drug release 
e.g.  zero  order  drug  release  is  not  desired.  Pulsatile  delivery 
system is also known as time controlled release system as it is 
independent of pH, enzymes, gastrointestinal motility etc. 
Many disease shows circardian rhythms in their pathophysiology. 
It is observed that diseases have predictable cyclic rhythms and 
that the timing of medication regimens can improve outcome in 
selected chronic conditions. For understanding concept of  
 
 
chronotherapeutics,  it  is  necessary  to  understand  following 
concepts: 
  Chronobiology:  It  is  the  science  concerned  with  the 
biological mechanism of the diseases according to a time 
structure. 
  Chronopharmacology:  Chronopharmacology  is  the 
science  concerned  with  the  variations  in  the 
pharmacological actions of various drugs over a period of 
time. 
  Chronopharmacokinetics  Chronopharmacokinetics 
involves study of changes in drug absorption, distribution, 
metabolism  and  excretion.Pharmacokinetic  parameters, 
which are conventionally considered to be constantin time, 
are influenced by different physiological functions displaying 
circadianrhythm.  Circadian  changes  in  gastric  acid 
secretion,gastrointestinal motility,gastrointestinal blood flow, 
drug protein binding, liver enzyme activity, renalblood flow 
and urinary pH can play role in time dependent variation of 
drugplasma concentrations. 
  Chronotherapy:  Co‐ordination  of  biological  rhythms  and 
medical treatment iscalledchronotherapy. 
  Chronotherapeutics: Chronotherapeutics is the discipline 
concerned  with  thedelivery  ofdrugs  according  to  inherent 
activities  of  a  disease  over  a  certainperiod  of  time.  It  is 
becoming  increasingly  more  evident  that  the  specific 
timethat patients take their medication may be even more 
significant  than  wasrecognized  in  the 
past.Chronopharmaceutics  consist  of  two  words 
chronobiology  and  pharmaceutics.Chronobiology  is  the 
study of biological rhythms and their mechanisms. 
 
Thereare three types of mechanical rhythms in our body.[7, 8] 
1.  Circadian:- This word comes from Latin word ―circa means 
about and―dies means day. 
2.  Ultradian:-  Oscillation  of  shorter  duration  are  termed  as 
ultradian (more thanone cycle per 24h) less than one cycle 
per day. 
3.   Infradian:- Oscillations that are longer than 24 h (less than 
one cycle perday). 
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Figure 1: Schematic diagram of circadian rhythm showing diseases require PDDS 
 
 
 
Table:1 Influence of circardian rhythm on physiological functioning [10]
Sr. no.  Physiological function  Changes in functioning 
1  Body temperature  Decrease in sleep, Increase in wakefulness 
2  Breathing  Decrease in sleep, Increase in wakefulness 
3  Blood pressure  Decrease in sleep, Increase in wakefulness 
4  Growth hormone  At 11 pm secretion increase 
5  Adrenaline  At 11 pm secretion increase 
6  Heart rate  Decrease in sleep, Increase in wakefulness 
7  Catecholamines  Increase in morning  
8  Plasma aggregability  Increase in morning 
9  Fibrinolytic activity  Decrease in morning 
10  Gastric acid secretion  Highest in evening 
11  Gastric emptying  Increase in morning 
 
Figure 2: Drug Release Patterns:  A) Pulsatile B) And C) Other Conventional Extended Release Dosageforms [9] 
 
Requirnments Of Pulsatile Delivery Systems:[11-13] 
Sustained delivery systems are not always able to fulfill all the 
needs of some diseases at that time dosage form that can release 
drugs after lag time or not releasing drugs in early phase of drug 
administration. In such case pulsatile delivery is the most effective 
way of treatment. 
1. Many body functions follow circadian rhythm, i.e., their activity 
increases  ordecreases  with  time.  A  number  of  hormones  like 
rennin,  aldosterone,  and  cortisolshow  daily  as  well  as  timely Maunitkumar et al.                                                                                                    Mintage journal of Pharmaceutical & Medical SciencesI 4-11 
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fluctuations  in  their  blood  levels.  Circadian  effects  arealso 
observed in case of pH and acid in these cases pulsatile delivery 
system is the preffered one. 
2. salbutamolsulphate is the drug which develop tolerance in the 
human body when given assustained release dosage form. Many 
patients are required to upgrade their dosage regimen after one-
year under treatment using transdermal clonidine patches Arterial 
pressure in patientsexceeds the pretreatment value during the 3–
7 days followingremoval of their previoustransdermal nitroglycerin 
patch. All these conditions can be treated effectively by pulsatile 
delivery systems. 
3. some drugs undergo extensive first pass metabolism such as 
beta blocker, salicylamide  and require fast drug input in order to 
saturate  metabolizing  in  order  to  minimize  pre  systemic 
metabolism.  Thus  a  constant/sustained  oral  method  of  delivery 
would result in reduced oral bioavailability. 
4.  Circadian  rhythms  in  certain  physiological  functions  are  well 
established.  It  has  beenrecognized  that  many  symptoms  and 
onset of disease occur during specific time periods of the 24 hr 
period  day.  E.g.:  asthma  and  angina  pectoris  attacks  occur 
generally in early morning. 
5. Local treatment: In order to obtain effective drug treatment for 
local  disorders  such  as  inflammatory  bowel  disease  delivery  of 
compounds  to  the  site  of  inflammation  with  no  loss  due  to 
absorption in the small intestine is highly desirable to achieve the 
therapeutic effect and to minimizeside effects. 
6. Protection from gastric environment is essential for the drugs 
that undergodegradation in gastric acidic medium (e.g., peptide 
drugs), irritate the gastric mucosa(NSAIDS) or induce nausea and 
vomiting. These conditions can be satisfactorilyhandled by enteric 
coating, and in this sense, enteric coating can be considered as 
apulsatile drug delivery system. 
Advantages:[14-16] 
  Predictable,  reproducible  and  short  gastric  residence 
time 
  Less inter- and intra-subject variability 
  Bioavailability improved 
  Reduction of local irritation 
  No  dose dumping observed 
  Flexibility in design 
  Stability gets improved 
Disadvantages:[17, 18] 
  Lack of manufacturing reproducibility and efficacy 
  Numbers of process variables are high 
  Cost of production is high 
  Trained/skilled personnel are needed for manufacturing 
  Less inter- and intra-subject variability 
  Improve patient comfort and compliance 
  Achieve a unique release pattern 
  Extend  patent  protection,  globalize  product,  and 
overcome competition 
  Reduced adverse effects and improved tolerability 
 
Diseases targeted for Pulsatile Drug Delivery System:[19-24] 
Diseases  targeted  by  pulsatile  delivery  systems  are  hyper 
cholesteromia,  asthma,  ulcer,  arthritis,diabeteus,  neurological 
disorders, cardiovascular disease and colonic delivery. 
Hypercholesterolemia  
A  circardian  changes  are  observed  during  hepatic  cholesterol 
synthesis.  Therefore  cholesterol  synthesisoccur  higher  in 
concentration during night than day time particularly early in the 
morning. 
Asthma 
The chronotherapy of asthma has been widely studied. Air way 
resistance  increasesprogressively  at  night  or  early  morning  in 
asthmatic  patients.Normal  lung  functions  showscircardian 
changes which reaches a low point in the early morning hours. 
Broncho  constriction  and  worsening  of  symptoms  observed  in 
circardian fashion so chronotherapy is well suited for asthma. 
Arthrities 
The chronobiology, Chronopharmacology and chronotherapeutics 
of pain have been widely studied. Circardian rhythm observed in 
interleukin  6  and  c  reactive  protein  of  patients  with  arthritis. 
Patients with osteoarthritis shows less pain in the morning and 
more  at  night  while  patients  suffering  with  rheumatoid  arthritis 
shows  less  pain  in  the  night  and  more  pain  in  the  early 
morning.Chronotherapy  has  been  selected  in  such  a  way  that 
highest drug level observed at the right time for effective treatment 
of diseases. 
Diabeteus 
The circadian variations of glucose and insulin in diabetes have 
been extensively studied.The goal of insulin therapy is to mimic 
the normal physiologic pattern of endogenous insulin secretion in 
healthy  individuals,  with  continuous  basal  secretion  as  well  as 
meal-stimulated secretion.  
Neurological disorders 
Central mechanisms of epilepsy showscircardian rhythm. Various 
convulsive events shows circardian rhythm and chronotherapy is 
the considered one for effective treatment. 
Cardiovascular diseases 
Several functions such as, Blood pressure (BP), heart rate, stroke 
volume, cardiac output, blood flow of the cardiovascular system is 
subject  to  circadian  rhythms.  For  instance,  capillary  resistance 
and vascular reactivity are higher in the morning and decrease 
later in the day. Platelet aggregability is increased and fibrinolytic 
activity is decreased in the morning, leading to a state of relative 
hypercoagulability of the blood. It was postulated that modification 
of these circadian triggers by pharmacologic agents may lead to 
the  prevention  of  adverse  cardiac  events.  BP  is  at  its  lowest 
during  the  sleeping  period  and  rises  steeply  during  the  early 
morning period. Most patients with essential hypertension have a 
similar  circadian  rhythm  of  BP  as  do  normotensive  persons, 
although hypertensive patients have an upward shift in the profile  
Colonic delivery 
There is low proteolytic activity observed at site of colon so it is 
the preffered absorption site for absorption of protein and peptide 
drugs. A colon specific delivery system prevent drug release in 
stomach and small intestine and upon entry in colon sudden drug 
rlease in pulsatile fashion occurs.colon targeted delivery system 
also named as time specific delivery system. Here in this case lag 
time is the time required for the dosage form to reach at colon. 
All these diseases require to deliver drugs in right amount and at 
right  time and site. Pulsatile delivery system is the only dosage 
form which can fulfill the needs of these diseases. 
Methodologies for the PDDS can be broadly classified into 
four classes:[24] 
I. Time controlled pulsatile release 
A. Single unit system 
B. Multi-particulate system 
II. Stimuli induced 
A. Thermo-Responsive Pulsatile release 
B.Chemical stimuli induced pulsatile systems 
III. External stimuli pulsatile release 
A. Electro responsive pulsatile release 
B. Magnetically induced pulsatile release Maunitkumar et al.                                                                                                    Mintage journal of Pharmaceutical & Medical SciencesI 4-11 
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IV.  Pulsatile  release  systems  for  vaccine  and  hormone  products 
Table: 2 Diseases treated by pulsatile delivery systems 
NO.  Diseases  Conditions  Drugs 
1  Peptic ulcer  Acid secretion is high in afternoon and night  H2 blockers 
2  Duodenal ulcer  Gastric secretion high at night while gastric and small bowel motility and gastric 
emptying are slower at night  
Proton pump inhibitors 
3  Neurological disorder  Central patho physiology of epilepsy and behavioural classification of convulsive 
events in  
MAO-B inhibitors 
4  Attention  deficient 
disorder 
Increase DOPA in afternoon  Methyl phenidate 
5  Hyper 
cholesterolemia 
Cholesterol synthesis high in night than day  HMG  CoA  reductase 
inhibitors 
6  Diabeteus mellitus  Increase blood sugar level after meal  Sulfonyl urea, 
Insulin 
7  Osteoartheities  Level of pain increase in night and decrease throughout day  NSAIDS, 
Glucocorticoids 
8  Rheumatoid arthritis  Level of pain increase in early morning and less at night  NSAIDS, 
Glucocorticoids 
9  Asthma  Precipitation of attack in night and early morning  2 agonist, 
Anti histamines 
10  Cardiovascular 
disease 
BP(Blood  pressure)  is  lowest  at  sleep  cycle  and  rised  sharply  during  early 
morning 
Nitroglycerine, 
calcium  channel 
blocker,ACE inhibitors 
11  Cancer  The blood flow to tumours three fold greater during each daily activity phase of 
the circardian cycle than during the daily rest phase 
Vinca alkaloid, taxanes 
 
I. Time controlled pulsatile release 
A. Single unit system [25] 
A.1 capsular system 
Different  single-unit  capsular  PDDS  are  available.  A 
generaldesign  of  suchsystemsconsists  of  an  insoluble  capsule 
body  insisting  a  drug  and  a  plug.  The  plug  isremoved  after 
apredetermined  time  lag  due  to  various  mechanisms  such  as 
swelling,  erosion,  or  dissolution.  ThePulsincap®  system  is  an 
example  of  such  a  system  that  is  made  up  of  a 
waterinsolublecapsule body filled with drug formulation. The plug 
material consists ofvarious polymeric materials such as insoluble 
but permeable and swellable polymers (e.g.: polymethacrylates),  
 
 
erodiblecompressed  polymers  (e.g.:  hydroxypropylmethyl 
cellulose, polyvinyl alcohol,polyethylene oxide), congealed melted 
polymers(e.g.:saturatedpolyglycolatedglycerides,glycerylmonoole
ate and enzymatically controlled erodible polymer (e.g.:pectin). 
A.2.Port systems:- 
The Port System consists of a gelatin capsule coated with a semi 
permeablemembrane  (e.g.:  cellulose  acetate)  housing  an 
insoluble plug (e.g.: lipidic) and anosmotically active agent along 
with  the  drug  formulation.  When  it  comes  in  contactwith  the 
aqueous  medium,  water  diffuses  across  the  semi  permeable 
membrane,resulting  in  increased  inner  pressure  that  ejects  the 
plug  after  a  lag  time.Thickness  of  semi  permeable  membrane 
determines the lag time.  Port system shows the good correlation 
between in vivo and in vitro experiments. 
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Figure 2: Port System 
 
A.3 Delivery by a series of stops:- 
Implantable  capsules  are  the  example  of  such  systems.  The 
capsule contains a drug and awater-absorptive osmotic agent that 
are placed in compartments separated by amovable partition. The 
pulsatile delivery is achieved by a series of stops along theinner 
wall of the capsule. These stops obstruct the movement of the 
partition but areovercome in succession as the osmotic pressure 
rises  above  a  threshold  level. Porcine  and  somatotropine  have 
been delivered by this system. 
A.4 Delivery by solubility modulation:- 
Solubility modulators are available for pulsatile delivery of variety 
of drugs.Salbutamol sulphate is the best example. This system 
comprises the drug (salbutamol sulphate) and a modulating agent, 
sodiumchloride (NaCl). The amount of NaCl was such that it was 
less than the amountneeded to maintain saturation in a fluid that 
enters the osmotic device. The pulsed delivery obtained based on 
solubility of drugs. 
A.5  Delivery  by  reservoir  systems  with  erodible  or  soluble 
barrier coatings:- 
Reservoir devices coated with a barrier layer are the most widely 
observed  pulsatile  drug  delivery  systems.Most  of  the  pulsatile 
drug delivery systems are. This barrier erodes or dissolves after a 
specific lag period, and the drug issubsequently released rapidly. 
Thickness of the coating layer decides the lag time of system.The  
Time Clock® system consists of a solid dosage form coated with 
lipid barrierscontaining carnauba wax and bees  wax along  with 
surfactants,  such  aspolyoxyethylenesorbitanmonooleate.  This 
coat  erodes  oremulsifies  in  the  aqueousenvironment  in  a  time 
proportional  to  the  thickness  of  the  film,  and  the  core  is 
thenavailable for dispersion. 
The  Chronotropic®  system  consists  of  a  drug-containing  core 
coated by hydrophilicswellablehydroxypropylmethyl cellulose  
(HPMC), which is responsible for a lagphase in the onset of drug 
release. 
B. Multiparticulate Systems 
Multi-particulate  drug  delivery  systems  are  mainly  oral  dosage 
forms consisting of amultiplicity of small discrete units, in which 
the active substance is present as anumber of small independent 
subunits.There are different types of multiparticulate systems and 
these are enumerated andexplained below: 
B.1 Pulsatile System Based on Rupturable Coating:- 
This is a multiparticulate system in which drug is coated on non-
pareil sugar seedsfollowed by a swellable layer and an insoluble 
top layer. Superdisintegrants like sodium carboxymethyl cellulose, 
sodium starchglycollate, L-hydroxypropyl cellulose, etc are use as 
swelling agents. Expansion of  swellable layer occurs after ingress 
of water, resulting in rupture of film with subsequent rapid drug 
release. 
B.2 Time controlled expulsion system:- 
Combination  of  osmotic  and  swelling  action  is  used  for  time 
controlled  expulsion  system.  The  corecontains  the  drug,  a  low 
bulk density solid and/or liquid lipid material (e.g., mineraloil) and 
a  disintegrant.  Cellulose  acetate  is  further  used  for  coating  of 
core. Uponimmersion in aqueous medium, water penetrates the 
core  displacing  the  lipid  material.After  the  depletion  of  lipid 
material,  internal  pressure  increases  until  a  critical  stress 
isreached, which results in rupture of the coating material. 
B.3 Pulsatile Delivery by Change in Membrane Permeability:- 
The  permeability  and  water  uptake  of  acrylic  polymers  with 
quaternary ammoniumgroups can be influenced by the presence 
of different counter-ions in the medium.Several delivery systems 
based  on  this  ion  exchange  have  been  developed.  EudragitRS 
30D is reported to be a polymer of choice for this purpose. 
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Figure 4: System Based on Rupturable Coating 
 
B.4 Sigmoidal Release System:- 
This consists of pellet cores comprising drug and succinic acid 
coated  withammoniomethacrylatecopolymer  USP/NF  type  B. 
water  influx  through  permeable  membrane  determines  the  lag 
time.. The water dissolves acid and the drug inthe core. The acid 
solution in turn increases permeability of the hydrated polymerfilm. 
B.5 Low density floating multiparticulate pulsatile systems:- 
Conventional  multiparticulate  pulsatile  release  dosage  forms 
mentioned  above  arehaving  longer  residence  time  in  the 
gastrointestinal tract and due to highly variablenature of gastric 
emptying  process  may  result  in  in  vivo  variability  and 
bioavailabilityproblems.  In  contrary,  low  density  floating 
multiparticulate pulsatile dosage formsreside only in stomach and 
not  affected  by  variability  of  pH,  local  environment  orgastric 
emptying  rate.  Drugs  either  absorbed  from  the  stomach  or 
requiring local delivery in stomach these dosage forms are also 
specificallyadvantageous fordelivery of those types of drugs. 
II. Stimuli induced[26
-28] 
A. Temperature induced systems 
Thermo-responsive  hydrogel  systems  have  been  developed  for 
pulsatile  delivery  systems.  Inthese  systems  the  polymer 
undergoes  swelling  or  deswelling  phase  in  response  to 
thetemperature which modulate drug release in swollen state. 
B.Chemical stimuli induced pulsatile systems [29, 30] 
B.1Glucose-responsive insulin release devices:- 
In  case  of  Diabetes  mellitus  there  is  rhythmic  increase  in  the 
levels of glucose in thebody, requiring injection of the insulin at 
proper time. Several systems have beendesigned which are able 
to respond to changes in glucose concentration. One suchsystem 
includes  pH  sensitive  hydrogel  containing  glucose  oxidase 
immobilized  in  thehydrogel.  When  glucose  concentration  in  the 
blood  increases  glucose  oxidase  convertsglucose  into  gluconic 
acid which changes the pH of the system. Swelling of the polymer 
observed  due  to  pH  change  which  results  in  insulin  release. 
Examples  of  the  pHsensitive  polymers  include  N,  N-
dimethylaminoethyl methacrylate, chitosan, polyoletc. 
B.2 Inflammation-induced pulsatile release:- 
On  receiving  any  physical  or  chemical  stress,  such  as  injury, 
fracture etc., inflammation take place at the injured sites. Hydroxyl 
radicalsare  produced  due  to  inflammation  from  these 
inflammation-responsive  cells.  Degradation  via  hydroxylradicals 
however, is usually dominant and rapid when Hyaluronic Acid gel 
is injectedat inflammatory sites. These gels are used for delivery 
of drugs to particular inflamed sites. 
B.3Drug release from intelligent gels responding to antibody 
concentration:- 
There are numerous kinds of bioactive compounds which exist in 
the body. Recently,novel gels were developed which responded to 
the change in concentration ofbioactive compounds to alter their 
swelling/deswelling  characteristics.  Antigen-antibodycomplex 
formation  as  the  cross-linking  unitsin  the  gel  gained  special 
attention, since such interaction is very specific. 
B.4 pH sensitive drug delivery system:- 
This  type  of  PDDS  contains  two  components.  The  first  is  fast 
release type and the other one is  pulsed release which releases 
the drug in response to change in pH. In case ofpH dependent 
system, advantage has been taken of the fact that there exists 
differentpH environment at different parts of the gastrointestinal 
tract.  Examples  of  pHdependent  polymers  include  cellulose 
acetate  phthalate,  polyacrylates,  and 
sodiumcarboxymethylcellulose. 
III. External stimuli pulsatile release [31-33] 
This  system  was  divided  into  three  subparts  and  is  discussed 
below. 
A. Electro responsive pulsatile release:- 
Polyelectrolytes  (polymers  which  contain  relatively  high 
concentration of ionisable groups along the backbone chain) are 
used  for  preparing  electrically  responsive  delivery  systems  and 
are thus, pH-responsive as well as electro-responsive. Examples 
ofnaturally occurring polymers include hyaluronic acid, chondroitin 
sulphate etc. 
B. Micro electro mechanical systems (MEMS):- 
A  micro  fabricated  device  has  the  ability  to  store  and  release 
multiple chemicalsubstances on demand by a mechanism devoid 
of  moving  its  parts.  The  digitalcapabilities  of  MEMS  may  allow 
greater temporal control over drug release comparedto traditional 
polymer-based systems. The micro chip is the other development 
in the MEMS. The microchip consists of an array of reservoirs that 
extend through anelectrolyte-impermeable substrate. 
C. Magnetically induced pulsatile release:- 
The use of an oscillating magnetic field to modulate the rates of 
drug  release  frompolymer  matrix  was  one  of  the  old 
methodologies. Magnetic carriers receive theirmagnetic response 
to  a  magnetic  field  from  incorporated  materials  such  as 
Magnetite,Iron,  Nickel,  Cobalt  etc.  For  biomedical  applications, 
magnetic  carriers  must  be  waterbasedbiocompatible,  non-toxic 
and non-immunogenic mechanistic approach. 
IV.  Pulsatile  release  systems  for  vaccine  and  hormone 
products 
Vaccines  are  traditionally  administered  as  an  initial  shot  of  an 
antigen followed byrepeated booster shots to produce protective 
immunity. The frequency of the boostershots, and hence the exact 
immunization  schedule  is  antigen  dependent.  Also, 
coadministrationof vaccine adjuvant is often required to enhance 
the immune responseto achieve protective immunity. PDDS offer 
the possibility of single-shot vaccines. 
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Table: 3 Registered trademark for pulsatile delivery system available in market:[34] 
No.  Registered 
trademark® 
Drug  Timing of drug 
administration 
Indications for 
chronotherapy 
1  Aciphex  Rabeprazole 
Sodium 
After morning meal  Healing of duodenal 
Ulcers 
2  Cardizem LA  DilitiazemHCl  Bedtime  Hypertension 
3  Cardura XL  Doxazosin 
Mesylat 
Administered with 
breakfast 
Benign prostatic 
Hyperplasia 
4  Covera-HS  Verapamil HCL  Bedtime  Hypertension 
5  Procardia XL  Nifedipine  Bedtime  
 
Angina pectoris/ 
Hypertension 
6  Ritalin LA  Methylphenidate 
HCl 
Morning  
 
Attention deficit 
Hyperactiy 
7  Lodotra  Prednisone  Bedtime 
(4 h after ingestion) 
Rheumatoid arthritis 
8  Procardia XL  Nifedipine  Bedtime  Angina pectoris/ 
hypertension 
9  Uniphyl  Theophylline  bedtime   Asthma 
10  Verelan PM   Verapamil HCl  Bedtime   Hypertension 
 
Recent  Techniques  of  Oral  Time  Controlled  Pulsatile 
Technology 
Currently,  pharmaceutical  companies  have  been  focused  on 
developing  andcommercializing  PDDS  that  fulfill  unmet  medical 
needs  in  the  treatment  of  variousdiseases.  Recently  developed 
technologies  are  SODAS®  Technology,  IPDAS®Technology, 
CODAS™  Technology,GEOCLOCK®  Technology, 
PULSYS™Technology,  Eurand’s  pulsatile  and  Chrono  Release 
System, MagneticNanocomposite Hydrogel. 
Conclusion 
Sustained delivery system is not beneficial particularly in case of 
treating diseases which follows circardian rhythm but in this case 
pulsatile  delivery  system  is  very  much  useful.  For  determining 
optimum need of drug in the body circardian rhythm of the body is 
an  important  concept.  Pulsatile  delivery  system  is  the  system 
which provides drug release at right amount, right time and at right 
site.  Chronotropic  systems  are  an  emerging  approach  to  drug 
delivery. In this review article we describe advantages of pulsatile 
delivery system and also recent marketed preparations available 
as pulsatile dosage forms. There are various technologies present 
in  the  market  based  on  the  various  methodologies.  Thus, 
development  of  proper  pulsatile  drug  delivery  will  enhance  the 
patient  compliance,  optimum  drug  delivery  to  the  target  side  & 
minimizing the side effects. 
REFERENCES 
1.  Pavan P. CP. PULSATILE DRUG DELIVERY SYSTEM: AN 
OVERVIEW. Asian Journal of Pharmaceutical Sciences and 
Clinical Research. 2011;1(1):44-51. 
2.  Kumar  SSaN.  PULSATILE  DRUG  DELIVERY: 
CURRENTSCENARIO. CRIPS. 2007;8(2):27-33. 
3.  Dubal  ashwini  KA,  Ramana  MV  Patel  Mitul,Desai  Omkar. 
Chronotherapy a novel drug delivery. international journal of 
Ayurveda and pharmacy. 2011;2(6):1692-700. 
4.  P.Rathee,  A.Hooda,  S.Rathee,  et  al.  A  BIOLOGICAL 
RHYTHM-GUIDED  APPROACH  TO  DRUG  DELIVERY: 
CHRONOPHARMACEUTICS.  International  journal  of 
institunal pharmacy and life sciences. 2011;1(2):151-82. 
5.  M.Rao, N. Gajanan, S.Borate, et al. Design, Evaluation and 
Comparative  Study  of  Pulsatile  Release  from  Tablet  and 
Capsule  Dosage  Forms.  Iranian  journal  of  pharmaceutical 
sciences. 2009;5(3):119-28. 
6.  K. Patil, M. Mule, Uppl H. MODIFIED RELEASE, SINGLE 
PULSATILE  DRUG  DELIVERY  SYSTEM:  A  REVIEW. 
International  Journal  Of  Pharmacy&Technology. 
2011;3(4):1673-95. 
7.  Haus E. Chronobiology in the endocrine system. Advanced 
drug delivery reviews. 2007;59:985-1014. 
8.  T.Berthold. Clinical implications of pulsatile hormone signals. 
Growth Hormone & IGF Research. 2001;A:1-8. 
9.  R.Mayee,  P.Shinde,  P.Mane.  A  REVIEW:  CURRENT 
REPORTED TECHNOLOGIES USED IN PULSATILE DRUG 
DELIVERY  SYSTEM.  International  journal  of  pharmacy  & 
research. 2012;2(1):23-30. 
10.  S. Lin, Kawashima Y. Chronotherapeutic approach to design 
a thermoresponsive membrane for transdermal drug delivery. 
Current drug delivery. 2004;1:249-63. 
11.  K.  Bhandwalkar,  S.Tamizarasi,  H.  Naidu,  et  al.  RECENT 
TRENDS  IN  PULSATILE  DRUG  DELIVERY  SYSTEMS: A 
REVIEW. International journal of institunal pharmacy and life 
sciences. 2012;2(3):167-85. 
12.  A.  D'souza,  K.Sutar,  P.Sutar,  et  al.  THE  USE  OF 
CHRONOPHARMACEUTICS  IN  DESIGN  OF  PULSATILE 
DELIVERY SYSTEMS-A REVIEW Journal of pharmaceutical 
and scientific innovation. 2012;1(2):50-5. 
13.  V.  Jain,  Singh  R.  Design  and  characterization  of  colon-
specificDrug  DeliverySystem  containing  Paracetamol 
microsponge.  Archieves  of  Pharmacal  research. 
2011;34(5):733-40. 
14.  K. Moin, Vishnu P. Pulsatile Drug Delivery System for Colon 
–  A  Review.  International  journal  of  research  in 
pharmaceutical and biomedical sciences. 2011;2(3):934-41. 
15.  Gopi  V.  New  Tool  for  Timed,Pulsatile  Drug  Delivery. 
Pharmaceutical formulation and quality. 2005. 
16.  D. Hitesh, Jayvadan P. Chronpharmaceutics, pulsatile drug 
delivery  system  as  current  trend.  Asian  journal  of 
pharmaceutical sciences 2010;5(5):207-30. 
17.  A.  Alexander,  N.  Bhoyar,  M.  Sharma,  et  al.  Important 
Aspects  and  Fundamentals  of  Chronotherapeutic  Drug 
Delivery System for Optimizing Therapeutic Effect. A Review. 
American  Journal  of  PharmTech  Research.  2012;2(2):755-
91. 
18.  G.RASVE, G. BORADE, S. DESHMUKH, et al. PULSATILE 
DRUG  DELIVERY  SYSTEM:  CURRENT  SCENARIO. 
International journal of pharma and bio science. 2011;2(3). 
Epub 332. 
19.  Bi-Botti  C.  Chronopharmaceutics:  gimmick  or  clinically 
relevant  approach  to  drug  delivery?  Journal  of  controlled 
release. 2004;98:337-53. 
20.  A. Sattwa, N. Biswas, K. Masud Karim, et al. Drug delivery 
system  based  on  chronobiology—A  review.  Journal  of 
controlled release. 2010;147:314-25. 
21.  S.Tajane,  B  Kholwal,  S.Suryawanshi,  et  al.  CURRENT 
TRENDS  IN  PULSATILE  DRUG  DELIVERY  SYSTEMS. 
INternational  journal  of  Pharmaceutical  sciences  and 
research. 2012;3(2):358-66. 
22.  R.  Trivedi,  K.  Wadher,  J.Taksande,  et  al. 
CHRONOTHERAPY:  A  CONCEPT,  PAUPERISM  AND Maunitkumar et al.                                                                                                    Mintage journal of Pharmaceutical & Medical SciencesI 4-11 
Vol 3 Suppl 1, Feb 2014                                               www.mintagejournals.com                                                                                               11 
 
APPROCHES.  International  Journal  of  Pharmaceutical 
Development & Technology. 2011;1(1):1-10. 
23.  G. Sharma, M. Srikanth, P. Kumar, et al. Recent trends in 
pulsatile  drug  delivery  systems  -  A  review.  International 
journal of Drug Delivery. 2010;2:200-12. 
24.  N.Nainwal.  Chronotherapeutics  —  A  chronopharmaceutical 
approach to drug delivery in the treatment of asthma. Journal 
of controlled release. 2012;163:353-60. 
25.  S.  Jessy,  Amol  S.  ORAL  MULTIPARTICULATE  DRUG 
DELIVERY  SYSTEMS:  A  REVIEW.  International  research 
journal of pharmacy. 2011;2(2):22-7. 
26.  A. NAYAKI RAVULA, GOUD BA. RECENT ADVANCES IN 
ORAL PULSATILE DRUG DELIVERY. Journal of Advanced 
Pharmaceutical Sciences. 2011;1(1):57-62. 
27.  P.  JIGAR,  K.  ANEJA,  MAJUMDAR  S.  PULSATILE  DRUG 
DELIVERY  SYSTEM:  AN  "USER-FRIENDLY"  DOSAGE 
FORMS. JPRHC. 2010;2(2):204-15. 
28.  S.Sharma,  A.  Dutt  Sharma,  Saharawat  R.  PULSATILE 
DRUG  DELIVERY  SYSTEM:  A  REVIEW  AN  ADVANCED 
APPROACH.  International  journal  of  pharmacy  and 
technology. 2011;3(2):1179-88. 
29.  J Sajan, T. Cinu, A. Chacko, et al. Chronotherapeutics and 
Chronotherapeutic Drug Delivery Systems. Tropical Journal 
of Pharmaceutical Research. 2009;8(5):467-75. 
30.  A.Maroni, L. Zema, M. Dorly, et al. Oral pulsatile delivery: 
Rationale  and  chronopharmaceutical  formulations.  r. 
2010;158:1-8. 
31.  D.Jain,  R.Raturi,  V.  Jain,  et  al.  Recent  technologies  in 
pulsatile drug delivery systems. Biomatter. 2011;1(1):57-65. 
32.  B.  Garg,  G.  Gnanarajan,  Kothiyal  P.  Formulation  and 
Evaluation of Pulsatile Drug Delivery System of Rosuvastatin 
Calcium  Using  Different  Swelling  Polymers.  The  pharma 
innovation. 2012;1(7):61-7. 
33.  C.Wang, C.Yang, Y .Sheng, et al. Anti-inflammatory effect 
with  high  intensity  focused  ultrasound-mediated  pulsatile 
delivery of diclofenac. Biomaterials. 2012;33:1547-53 Epub  
34.  S.  Lin,  Kawashima  Y.  Current  status  and  approaches  to 
developing  press-coated  chronodelivery  drug  systems. 
Journal of controlled release. 2012;157:331-53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 